INMED PHARMACEUTICALS INC. Increase (Decrease) in Prepaid Expenses, Other
INMED PHARMACEUTICALS INC. (INM) reported Increase (Decrease) in Prepaid Expenses, Other of -$173.98 thousand for the 12-month period ending 2025-06-30, per its 10-K filed 2025-09-23.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpensesOther · last filed 2025-09-23
- INMED PHARMACEUTICALS INC. increase (decrease) in prepaid expenses, other for the quarter ending 2025-06-30 was -$186.13K.
- INMED PHARMACEUTICALS INC. increase (decrease) in prepaid expenses, other for the quarter ending 2025-03-31 was -$154.09K.
- INMED PHARMACEUTICALS INC. increase (decrease) in prepaid expenses, other for the quarter ending 2024-12-31 was $495.10K, a 44.86% decline year-over-year.
- INMED PHARMACEUTICALS INC. increase (decrease) in prepaid expenses, other for the quarter ending 2024-09-30 was -$328.87K.
- INMED PHARMACEUTICALS INC. increase (decrease) in prepaid expenses, other for fiscal 2025 was -$173.98K.
- INMED PHARMACEUTICALS INC. increase (decrease) in prepaid expenses, other for fiscal 2024 was -$20.28K.
- INMED PHARMACEUTICALS INC. increase (decrease) in prepaid expenses, other for fiscal 2023 was -$299.19K.
- INMED PHARMACEUTICALS INC. increase (decrease) in prepaid expenses, other for fiscal 2022 was -$190.66K, a 123.16% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expenses, Other 3 month | Increase (Decrease) in Prepaid Expenses, Other 6 month | Increase (Decrease) in Prepaid Expenses, Other 9 month | Increase (Decrease) in Prepaid Expenses, Other 12 month |
|---|---|---|---|---|
| 2025-06-30 | -$186.13K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23 | -$340.22K derived: sum of 2 quarters · filed 2025-09-23 | $154.89K derived: sum of 3 quarters · filed 2025-09-23 | -$173.98K 10-K · filed 2025-09-23 |
| 2025-03-31 | -$154.09K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12 | $341.01K derived: sum of 2 quarters · filed 2025-05-12 | $12.14K 10-Q · filed 2025-05-12 | -$528.79K derived: sum of 4 quarters · filed 2025-09-23 |
| 2024-12-31 | $495.10K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-12 | $166.24K 10-Q · filed 2025-02-12 | -$374.70K derived: sum of 3 quarters · filed 2025-09-23 | -$468.99K derived: sum of 4 quarters · filed 2025-09-23 |
| 2024-09-30 | -$328.87K 10-Q · filed 2024-11-14 | -$869.80K derived: sum of 2 quarters · filed 2025-09-23 | -$964.10K derived: sum of 3 quarters · filed 2025-09-23 | -$66.13K derived: sum of 4 quarters · filed 2025-09-23 |
| 2024-06-30 | -$540.94K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23 | -$635.23K derived: sum of 2 quarters · filed 2025-09-23 | $262.73K derived: sum of 3 quarters · filed 2025-09-23 | -$20.28K 10-K · filed 2025-09-23 |
| 2024-03-31 | -$94.29K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12 | $803.67K derived: sum of 2 quarters · filed 2025-05-12 | $520.65K 10-Q · filed 2025-05-12 | $323.48K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $897.96K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-12 | $614.94K 10-Q · filed 2025-02-12 | $417.77K derived: sum of 3 quarters · filed 2025-02-12 | $286.05K derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-09-30 | -$283.02K 10-Q · filed 2024-11-14 | -$480.19K derived: sum of 2 quarters · filed 2024-11-14 | -$611.92K derived: sum of 3 quarters · filed 2024-11-14 | -$141.65K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$197.17K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30 | -$328.90K derived: sum of 2 quarters · filed 2024-09-30 | $141.37K derived: sum of 3 quarters · filed 2024-09-30 | -$299.19K 10-K · filed 2024-09-30 |
| 2023-03-31 | -$131.73K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-15 | $338.54K derived: sum of 2 quarters · filed 2024-02-13 | -$102.02K 10-Q · filed 2023-05-15 | -$616.34K derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-12-31 | $470.27K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-13 | $29.71K 10-Q · filed 2024-02-13 | -$484.61K derived: sum of 3 quarters · filed 2024-02-13 | $686.42K derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-09-30 | -$440.56K 10-Q · filed 2023-11-14 | -$954.87K derived: sum of 2 quarters · filed 2023-11-14 | $216.15K derived: sum of 3 quarters · filed 2023-11-14 | $3.19K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$514.31K derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-29 | $656.71K derived: sum of 2 quarters · filed 2023-09-29 | $443.75K derived: sum of 3 quarters · filed 2023-09-29 | -$190.66K 10-K · filed 2023-09-29 |
| 2022-03-31 | $1.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-15 | $958.06K derived: sum of 2 quarters · filed 2023-05-15 | $323.65K 10-Q · filed 2023-05-15 | -$46.11K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$212.96K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-17 | -$847.37K 10-Q · filed 2023-02-17 | -$1.22M derived: sum of 3 quarters · filed 2023-02-17 | $80.92K derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-09-30 | -$634.41K 10-Q · filed 2022-11-14 | -$1.00M derived: sum of 2 quarters · filed 2022-11-14 | $293.89K derived: sum of 3 quarters · filed 2022-11-14 | $157.08K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$369.76K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-23 | $928.30K derived: sum of 2 quarters · filed 2022-09-23 | $791.49K derived: sum of 3 quarters · filed 2022-09-23 | $823.17K 10-K · filed 2022-09-23 |
| 2021-03-31 | $1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-13 | $1.16M derived: sum of 2 quarters · filed 2022-05-13 | $1.19M 10-Q · filed 2022-05-13 | $1.39M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | -$136.81K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-14 | -$105.13K 10-Q · filed 2022-02-14 | $93.86K derived: sum of 3 quarters · filed 2022-02-14 | $79.36K derived: sum of 4 quarters · filed 2022-02-14 |
| 2020-09-30 | $31.68K 10-Q · filed 2021-11-10 | $230.67K derived: sum of 2 quarters · filed 2021-11-10 | $216.16K derived: sum of 3 quarters · filed 2021-11-10 | $242.35K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $198.99K derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-24 | $184.48K derived: sum of 2 quarters · filed 2021-09-24 | $210.67K derived: sum of 3 quarters · filed 2021-09-24 | $126.56K 10-K · filed 2021-09-24 |
| 2020-03-31 | -$14.51K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-13 | $11.68K derived: sum of 2 quarters · filed 2021-05-13 | -$72.43K 10-Q · filed 2021-05-13 | |
| 2019-12-31 | $26.18K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-02-11 | -$57.92K 10-Q · filed 2021-02-11 | ||
| 2019-09-30 | -$84.11K 10-Q · filed 2020-12-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |